Working With Patients To Use AI Against Rare Diseases
An Interview With Tim Guilliams, CEO of Healx
Executive Summary
Tim Guilliams, CEO of Healx, talks about the company’s mission of creating from existing drugs new options for rare disease patients. The company is using artificial intelligence to find combination treatments against rare conditions, while working closely with patient groups as key partners in the development process. The goal: faster development timelines and cheaper therapies for patients.
You may also be interested in...
Snapshot: Highlights From The First Six Months Of 2020
A selection of features you might have missed from the first six months of 2020, covering key topics from COVID-19 strategies in medtech to an analysis of pipeline focus areas across the pharma sector. Click on each section to get the full story behind the data.
First Vaccine Approval For Janssen With Two-Dose Ebola Prophylactic
The two-part vaccine becomes the second against Ebola to get approval. Janssen is now collaborating with the World Health Organization on vaccine pre-qualification to get it to people in need.
COVID-19 Vaccine Expectations Are Ambitious Not Impossible
Johan Van Hoof, global head of vaccines at Janssen, talks to In Vivo about the company’s platform, how it is approaching COVID-19 research and the impact of today’s global pandemic on the future of vaccine R&D.
Need a specific report? 1000+ reports available
Buy Reports